(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property Organization
International Bureau

(43) International Publication Date
29 October 2020 (29.10.2020)

WIPO | PCT

(10) International Publication Number
WO 2020/219314 A1

(51) International Patent Classification:
A61K 39/395 (2006.01) *A61P 1/00* (2006.01)

(21) International Application Number:
PCT/US2020/028273

(22) International Filing Date:
15 April 2020 (15.04.2020)

(25) Filing Language: English

(26) Publication Language: English

(30) Priority Data:
62/836,910 22 April 2019 (22.04.2019) US

(71) Applicant: **ELI LILLY AND COMPANY** [US/US]; Lilly Corporate Center, Indianapolis, Indiana 46285 (US).

(72) Inventors: **FRIEDRICH, Stuart William**; c/o Eli Lilly and Company, P.O. Box 6288, Indianapolis, Indiana 46206-6288 (US). **POLLACK, Paul Frederick**; c/o Eli Lilly and Company, P.O. Box 6288, Indianapolis, Indiana 46206-6288 (US). **TUTTLE, Jay Lawrence**; c/o Eli Lilly and Company, P.O. Box 6288, Indianapolis, Indiana 46206-6288 (US).


(74) Agent: **SHARP, Robert L.** et al.; Eli Lilly and Company, P.O. Box 6288, Indianapolis, Indiana 46206-6288 (US).

(81) Designated States *(unless otherwise indicated, for every kind of national protection available)*: AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DJ, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IR, IS, JO, JP, KE, KG, KH, KN, KP, KR, KW, KZ, LA, LC, LK, LR, LS, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA, SC, SD, SE, SG, SK, SL, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, WS, ZA, ZM, ZW.

(84) Designated States *(unless otherwise indicated, for every kind of regional protection available)*: ARIPO (BW, GH, GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, ST, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, KM, ML, MR, NE, SN, TD, TG).

(54) Title: MIRIKIZUMAB FOR USE IN A METHOD OF TREATING CROHN'S DISEASE

(57) Abstract: The present invention generally relates to the treatment of Crohns Disease with an anti-IL-23p19 antibody, particularly dosage regimens for the treatment of the disease.



Average serum concentrations of mirikizumab during the induction period in the study described in Example 1.

Figure 1.

WO 2020/219314 A1

[Continued on next page]

Declarations under Rule 4.17:

— *as to applicant's entitlement to apply for and be granted a patent (Rule 4.17(ii))*

— *as to the applicant's entitlement to claim the priority of the earlier application (Rule 4.17(iii))*

Published:

— *with international search report (Art. 21(3))*